Aptorum Group Limited Regains Compliance with NASDAQ’s Minimum Bid Price Requirement
Aptorum Group (NASDAQ: APM) has successfully regained compliance with Nasdaq's minimum bid price requirement, following its Class A ordinary shares maintaining a closing bid price of at least $1.00 for 10 consecutive business days from July 16 to July 30, 2025. This achievement comes before the October 14, 2025 deadline set by Nasdaq.
Additionally, the company announced on July 14, 2025, that it has entered into a definitive agreement for an all-stock merger with DiamiR Biosciences, a developer of blood-based tests for brain health and other diseases. Upon completion of the merger, DiamiR Biosciences, which operates a CLIA-licensed, CAP-accredited clinical laboratory in New Haven, CT, will become a wholly-owned subsidiary of Aptorum Group.
Aptorum Group (NASDAQ: APM) ha riconquistato con successo la conformità al requisito minimo del prezzo di offerta di Nasdaq, dopo che le sue azioni ordinarie di Classe A hanno mantenuto un prezzo di chiusura di almeno 1,00 $ per 10 giorni lavorativi consecutivi dal 16 al 30 luglio 2025. Questo risultato è stato raggiunto prima della scadenza del 14 ottobre 2025 stabilita da Nasdaq.
Inoltre, la società ha annunciato il 14 luglio 2025 di aver stipulato un accordo definitivo per una fusione interamente in azioni con DiamiR Biosciences, un'azienda che sviluppa test del sangue per la salute cerebrale e altre malattie. Al completamento della fusione, DiamiR Biosciences, che gestisce un laboratorio clinico autorizzato CLIA e accreditato CAP a New Haven, CT, diventerà una controllata interamente posseduta da Aptorum Group.
Aptorum Group (NASDAQ: APM) ha recuperado con éxito el cumplimiento del requisito mínimo del precio de oferta de Nasdaq, tras mantener sus acciones ordinarias Clase A un precio de cierre de al menos 1,00 $ durante 10 días hábiles consecutivos desde el 16 hasta el 30 de julio de 2025. Este logro se produjo antes de la fecha límite del 14 de octubre de 2025 establecida por Nasdaq.
Además, la compañía anunció el 14 de julio de 2025 que ha firmado un acuerdo definitivo para una fusión totalmente en acciones con DiamiR Biosciences, desarrolladora de pruebas sanguíneas para la salud cerebral y otras enfermedades. Tras la finalización de la fusión, DiamiR Biosciences, que opera un laboratorio clínico con licencia CLIA y acreditación CAP en New Haven, CT, se convertirá en una subsidiaria de propiedad total de Aptorum Group.
Aptorum Group (NASDAQ: APM)는 2025년 7월 16일부터 7월 30일까지 10 영업일 연속으로 종가가 최소 1.00달러 이상을 유지하여 나스닥의 최소 입찰가 요건을 성공적으로 충족했습니다. 이 성과는 나스닥에서 정한 2025년 10월 14일 마감일 이전에 이루어졌습니다.
또한, 회사는 2025년 7월 14일에 뇌 건강 및 기타 질병에 대한 혈액 기반 검사 개발업체인 DiamiR Biosciences와의 전량 주식 교환 합병을 위한 최종 계약을 체결했다고 발표했습니다. 합병 완료 시, CLIA 인증과 CAP 인가를 받은 임상 실험실을 뉴헤이븐(코네티컷주)에 운영하는 DiamiR Biosciences는 Aptorum Group의 완전 자회사가 될 예정입니다.
Aptorum Group (NASDAQ : APM) a réussi à retrouver la conformité avec l'exigence minimale de prix d'offre de Nasdaq, après que ses actions ordinaires de classe A ont maintenu un cours de clôture d'au moins 1,00 $ pendant 10 jours ouvrables consécutifs du 16 au 30 juillet 2025. Cette réussite intervient avant la date limite du 14 octobre 2025 fixée par Nasdaq.
De plus, la société a annoncé le 14 juillet 2025 qu'elle avait conclu un accord définitif pour une fusion entièrement en actions avec DiamiR Biosciences, un développeur de tests sanguins pour la santé cérébrale et d'autres maladies. Une fois la fusion achevée, DiamiR Biosciences, qui exploite un laboratoire clinique agréé CLIA et accrédité CAP à New Haven, CT, deviendra une filiale à part entière d'Aptorum Group.
Aptorum Group (NASDAQ: APM) hat erfolgreich die Einhaltung der Mindestgebotspreisanforderung der Nasdaq wiedererlangt, nachdem seine Stammaktien der Klasse A vom 16. bis 30. Juli 2025 an 10 aufeinanderfolgenden Handelstagen einen Schlusskurs von mindestens 1,00 $ gehalten haben. Dieser Erfolg wurde vor der von der Nasdaq gesetzten Frist am 14. Oktober 2025 erreicht.
Zusätzlich gab das Unternehmen am 14. Juli 2025 bekannt, dass es eine endgültige Vereinbarung für eine reine Aktientauschfusion mit DiamiR Biosciences, einem Entwickler von blutbasierten Tests für die Gehirngesundheit und andere Krankheiten, unterzeichnet hat. Nach Abschluss der Fusion wird DiamiR Biosciences, das ein CLIA-lizenziertes und CAP-akkreditiertes klinisches Labor in New Haven, CT, betreibt, eine hundertprozentige Tochtergesellschaft der Aptorum Group.
- Regained Nasdaq compliance ahead of October 14, 2025 deadline
- Strategic merger with DiamiR Biosciences to expand diagnostic capabilities
- Acquisition of CLIA-licensed, CAP-accredited clinical laboratory through merger
- Previous non-compliance with Nasdaq minimum bid price requirement indicates stock price weakness
- All-stock merger structure may lead to potential shareholder dilution
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that it received formal written notification from The Nasdaq Stock Market, LLC (“Nasdaq”) confirming that the company has regained compliance with Nasdaq’s minimum bid price requirement.
The regaining of compliance is a result of the closing bid price of the company’s Class A ordinary shares being at least
The closing bid price has been
On July 14, 2025 Aptorum announced that it entered into a definitive agreement for an all-stock merger transaction with DiamiR Biosciences, a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA-licensed, CAP-accredited clinical laboratory in New Haven, CT. As a result of this transaction and subject to the customary closing conditions, DiamiR Biosciences will become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger.
About Aptorum Group
Aptorum Group Limited (Nasdaq: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. For more information, please visit the company’s website at www.aptorumgroup.com.
About DiamiR Biosciences
DiamiR is a private molecular diagnostics company focused on developing and commercializing minimally invasive tests offered through its CLIA/CAP-certified laboratory for early detection and monitoring of brain health conditions and other diseases in clinical trials and clinical practice settings. DiamiR’s proprietary platform technology, protected by over 50 issued patents worldwide, is based on quantitative analysis of organ-enriched, including brain-enriched and inflammation-associated, microRNA signatures in plasma for screening, patient stratification, as well as disease progression and treatment monitoring. In addition, DiamiR offers protein and genetic biomarker analyses. DiamiR collaborates with leading academic centers, disease foundations, and biopharma companies. For more information, please visit the company's website at www.diamirbio.com and connect with DiamiR on LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. These statements reflect the company’s current expectations and projections about future events and are based on assumptions. Actual results may differ materially from those projected.
For more information, please contact:
Aptorum Group Limited
Investor Relations Department
investor.relations@aptorumgroup.com
+44 20 80929299
FAQ
What was the minimum bid price requirement that Aptorum Group (APM) needed to meet for Nasdaq compliance?
When did Aptorum Group (APM) announce its merger with DiamiR Biosciences?
What type of company is DiamiR Biosciences that Aptorum Group (APM) is merging with?
What will happen to DiamiR Biosciences after the merger with Aptorum Group (APM)?
When was Aptorum Group (APM) initially notified about the Nasdaq compliance issue?
